JP7770191B2 - カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のための抗真菌剤 - Google Patents

カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のための抗真菌剤

Info

Publication number
JP7770191B2
JP7770191B2 JP2021568113A JP2021568113A JP7770191B2 JP 7770191 B2 JP7770191 B2 JP 7770191B2 JP 2021568113 A JP2021568113 A JP 2021568113A JP 2021568113 A JP2021568113 A JP 2021568113A JP 7770191 B2 JP7770191 B2 JP 7770191B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
candida auris
formula
compound
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532734A5 (https=
JPWO2020232037A5 (https=
JP2022532734A (ja
Inventor
アングロ・ゴンザレス，デイビット・エー
バラ，ステファン・アンドリュ
Original Assignee
サイネクシス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイネクシス，インコーポレーテッド filed Critical サイネクシス，インコーポレーテッド
Publication of JP2022532734A publication Critical patent/JP2022532734A/ja
Publication of JP2022532734A5 publication Critical patent/JP2022532734A5/ja
Publication of JPWO2020232037A5 publication Critical patent/JPWO2020232037A5/ja
Priority to JP2025076668A priority Critical patent/JP2025118765A/ja
Application granted granted Critical
Publication of JP7770191B2 publication Critical patent/JP7770191B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2021568113A 2019-05-16 2020-05-12 カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のための抗真菌剤 Active JP7770191B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076668A JP2025118765A (ja) 2019-05-16 2025-05-02 カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のためのイブレクサファンゲルプのような抗真菌剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849019P 2019-05-16 2019-05-16
US62/849,019 2019-05-16
PCT/US2020/032547 WO2020232037A1 (en) 2019-05-16 2020-05-12 Antifungal agents, like ibrexafungerp for candida auris decolonization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076668A Division JP2025118765A (ja) 2019-05-16 2025-05-02 カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のためのイブレクサファンゲルプのような抗真菌剤

Publications (4)

Publication Number Publication Date
JP2022532734A JP2022532734A (ja) 2022-07-19
JP2022532734A5 JP2022532734A5 (https=) 2023-06-21
JPWO2020232037A5 JPWO2020232037A5 (https=) 2023-06-21
JP7770191B2 true JP7770191B2 (ja) 2025-11-14

Family

ID=70861571

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568113A Active JP7770191B2 (ja) 2019-05-16 2020-05-12 カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のための抗真菌剤
JP2025076668A Withdrawn JP2025118765A (ja) 2019-05-16 2025-05-02 カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のためのイブレクサファンゲルプのような抗真菌剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076668A Withdrawn JP2025118765A (ja) 2019-05-16 2025-05-02 カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のためのイブレクサファンゲルプのような抗真菌剤

Country Status (14)

Country Link
US (1) US20220211684A1 (https=)
EP (1) EP3968986A1 (https=)
JP (2) JP7770191B2 (https=)
KR (1) KR20220009416A (https=)
CN (1) CN113905733A (https=)
AU (1) AU2020276595B2 (https=)
BR (1) BR112021022876A2 (https=)
CA (1) CA3140637A1 (https=)
EA (1) EA202193146A1 (https=)
IL (1) IL288165B1 (https=)
MA (1) MA55958A (https=)
MX (1) MX2021013899A (https=)
TW (2) TWI881977B (https=)
WO (1) WO2020232037A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250006380A (ko) 2023-07-03 2025-01-13 연세대학교 산학협력단 칸디다 아우리스에 대한 항진균제 스크리닝 방법 및 항진균용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191077A1 (en) 2017-04-10 2018-10-18 Scynexis, Inc. Antifungal agents used in combination
WO2018213641A1 (en) 2017-05-17 2018-11-22 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of candida species
WO2019028034A1 (en) 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
KR101686075B1 (ko) * 2008-08-12 2016-12-13 싸이넥시스, 인크. 항균제
MA43825A (fr) * 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
US20220117948A1 (en) * 2019-01-30 2022-04-21 Scynexis, Inc. Triterpenoid antifungals for the treatment of fungal osteo-articular infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191077A1 (en) 2017-04-10 2018-10-18 Scynexis, Inc. Antifungal agents used in combination
WO2018213641A1 (en) 2017-05-17 2018-11-22 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of candida species
WO2019028034A1 (en) 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen，MicrobiologyOpen，2018年，7(4)，p.1-29，DOI: 10.1002/mbo3.578，e00578
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation，Antimicrobial Agents and Chemotherapy，2017年，vol.61, Issue.5，pp.1-13，https://doi.org/10.1128/ AAC.02396-16，e02396-16

Also Published As

Publication number Publication date
CN113905733A (zh) 2022-01-07
TW202110441A (zh) 2021-03-16
EA202193146A1 (ru) 2022-02-11
US20220211684A1 (en) 2022-07-07
CA3140637A1 (en) 2020-11-19
MX2021013899A (es) 2022-02-10
IL288165B1 (en) 2026-01-01
KR20220009416A (ko) 2022-01-24
EP3968986A1 (en) 2022-03-23
AU2020276595A1 (en) 2021-12-09
AU2020276595B2 (en) 2025-12-04
TWI881977B (zh) 2025-05-01
WO2020232037A1 (en) 2020-11-19
JP2025118765A (ja) 2025-08-13
BR112021022876A2 (pt) 2022-04-12
JP2022532734A (ja) 2022-07-19
TW202602460A (zh) 2026-01-16
MA55958A (fr) 2022-03-23
IL288165A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
US20230364067A1 (en) Antifungal agents with enhanced activity in acidic ph
US20150031640A1 (en) Antibacterial agents: combination of a rifamycin and a switch region inhibitor
JP2025118765A (ja) カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のためのイブレクサファンゲルプのような抗真菌剤
JP2022539583A (ja) マイコプラズマ・ジェニタリウムによって引き起こされる感染症の治療のための組合せ
JP2020513037A (ja) 併用される抗真菌剤
JP7562542B2 (ja) 真菌性骨－関節感染症を治療するためのトリテルペノイド系抗真菌薬
HK40067174A (zh) 用於消除耳念珠菌移生的如依贝瑞芬赫普的抗真菌剂
CN113332277B (zh) 一种吡咯二酮化合物在制备抗真菌药物中的应用
EA048874B1 (ru) Противогрибковые агенты для деколонизации candida auris
ES3055272T3 (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
EA051506B1 (ru) Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251104

R150 Certificate of patent or registration of utility model

Ref document number: 7770191

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150